---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Cost-effectiveness evidence"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Cost-effectiveness evidence. Topics: Summary: price of darovasertib and drug cost inputs for the regimen and its comparators, Summary: eligible population inputs, Summary: health technology assessments and cost-effectiveness analyses of tebentafusp, Summary: liver-directed therapy and revenue estimates, and 21 further topics. 25 evidence topics quoted from 39 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics/cost-effectiveness"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary: price of darovasertib and drug cost inputs for the regimen and its comparators

No price, wholesale acquisition cost, budget impact model, or cost-effectiveness analysis of darovasertib or of the darovasertib plus crizotinib regimen was found. IDEAYA states that darovasertib, if approved for one or more designated indications, “may also be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act”.

- Crizotinib: Pfizer lists the wholesale acquisition cost of XALKORI at $23,773.10 per package of 60 capsules for both the 200 mg and 250 mg strengths, as Pfizer's published list price before any discount or rebate, accurate as of March 10, 2026. OptimUM-02 gives crizotinib 200 mg twice daily with darovasertib 300 mg twice daily; the XALKORI label's recommended dosage for ALK- or ROS1-positive metastatic NSCLC is 250 mg twice daily, with 200 mg twice daily as the first dose reduction. In OptimUM-02, median relative dose intensities were 91.0% for darovasertib and 77.1% for crizotinib, and median duration of treatment was 6.31 months.
- Tebentafusp: Immunocore lists KIMMTRAK 100 mcg/0.5 mL vial (NDC 80446-0401-01) at a wholesale acquisition cost of $22,050.00, effective 1 July 2026. The label dose is 20 mcg on Day 1, 30 mcg on Day 8, and 68 mcg on Day 15 and once every week thereafter, intravenously, until unacceptable toxicity or disease progression. CADTH notes that “Drug wastage is quite significant” because the standard dose is less than the vial size (68 mcg vs 100 mcg). Under the 2024 physician fee schedule, CMS granted KIMMTRAK an applicable percentage of unused or discarded product volume subject to refund of 45%, and Immunocore does not currently expect to make refund payments under the CMS Rule. Immunocore reports KIMMTRAK net revenue of $257.0 million in the United States for 2025.
- Pembrolizumab: Merck lists KEYTRUDA at $12,517.44 per dose given every 3 weeks and $25,034.88 per dose given every 6 weeks, current as of September 2026; the melanoma dose is 200 mg every 3 weeks or 400 mg every 6 weeks.
- No manufacturer-published U.S. list price of nivolumab, ipilimumab, dacarbazine, or the HEPZATO KIT was found. In the OptimUM-02 control arm, ipilimumab plus nivolumab was selected for 79 participants (76.7%) and pembrolizumab for 24, and no participant received dacarbazine; the topline release gives 76% (n=78) and 24% (n=25). Median duration of treatment was 2.87, 2.56, and 2.79 months for pembrolizumab, ipilimumab, and nivolumab.
- In Germany, the G-BA lists annual treatment costs per patient after statutory rebates of €605,881.61 to €619,990.00 for tebentafusp, €65,157.24 for ipilimumab, €75,915.32 to €76,207.30 for nivolumab, and €4,694.71 to €12,497.72 for dacarbazine.

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm); [Pfizer XALKORI Connecticut price disclosure (2026)](https://cdn.pfizer.com/pfizercom/products/ctprescribers/XALKORICTPriceDisclosureShortForm03122026.pdf); [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf); [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf); [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO); [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf); [Immunocore KIMMTRAK price change notice (2026)](https://www.immunocore.com/download_file/force/321/0); [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf); [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1); [Immunocore Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/imcr-20251231.htm); [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s195lbl.pdf); [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma); [G-BA resolution, tebentafusp reassessment D-995 (2024)](https://www.g-ba.de/downloads/91-1455-1022/2024-06-25_Current-Version_Tebentafusp_D-995_EN.pdf)

<a id="topic-4.1-2"></a>

### Summary: eligible population inputs

- Incidence of uveal melanoma: IDEAYA estimates an annual incidence of primary uveal melanoma of more than 3,000 patients in the United States and more than 10,000 globally. Castle Biosciences estimates approximately 2,000 patients diagnosed annually with uveal melanoma in the United States. The American Cancer Society estimates about 3,200 new cancers of the eye and orbit, mainly melanomas, in the United States in 2026. In the United States from 1975 to 2020, the mean age-adjusted incidence of primary uveal melanoma was 5.6 per million population (95% CI, 5.5 to 5.7); the National Cancer Institute gives approximately 4.3 new cases per million people.
- Metastatic disease: IDEAYA estimates an annual incidence of newly diagnosed metastatic uveal melanoma of approximately 1,500 in the United States and 4,000 to 5,000 globally, based on data suggesting that approximately 50% of patients diagnosed in the primary setting progress to metastatic disease. Published estimates of the share of patients who develop metastases are up to 50% and 40% or more; after treatment for choroidal melanoma, 5- and 10-year cumulative metastasis rates were 25% (95% CI, 23% to 27%) and 34% (95% CI, 32% to 37%).
- HLA-A∗02:01 status: IDEAYA states that HLA∗A2(-) patients represent “between 60-65% of all mUM patients” and that loss of heterozygosity could lead to over-reporting of HLA∗A2(+) prevalence in blood-based testing. HLA-A∗02:01-negative patients comprised 49% of individuals prescreened for a trial of tebentafusp. In a U.S. real-world cohort of 219 participants with metastatic uveal melanoma (Tempus database, 2019-2025), HLA-A∗02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%. Published articles state that HLA-A∗02:01-positive individuals account for 45% (or ~45%) of people in the United States and Europe, and that 40–50% of the European population express HLA-A∗02:01.
- Eligibility for tebentafusp: IDEAYA's presentation states “< 50% patients eligible for the only approved systemic therapy”, and Delcath states “Currently 55% of the patients are not eligible for KIMMTRAK”.

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm); [Castle Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1447362/000162828026012272/cstl-20251231.htm); [American Cancer Society key statistics for eye cancer (2026)](https://www.cancer.org/cancer/types/eye-cancer/about/key-statistics.html); [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/); [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq); [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Carvajal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36600005/); [Diener-West et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16344433/); [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext); [Salama et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/contemporary-real-world-patient-characteristics-treatment-patterns-and-clinical-outcomes-in-metastatic-uveal-melanoma-in-the-united-states); [de Melo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11299924/); [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/); [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/); [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf); [Delcath Systems Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/872912/000162828026012019/dcth-20251231.htm)

<a id="topic-4.1-3"></a>

### Summary: health technology assessments and cost-effectiveness analyses of tebentafusp

- NICE recommends tebentafusp for HLA-A∗02:01-positive unresectable or metastatic uveal melanoma only with the company's commercial arrangement; the list price is £10,114 per 200 microgram vial. The company's 3-state partitioned survival model used a starting age of 62 years, a 38-year time horizon, utility values by time to death, and the costs of HLA-A∗02:01 testing. With the end-of-life criteria, the acceptable ICER was around £39,000 per QALY gained; the ICERs are confidential. The resource impact report projects 120 to 125 people eligible each year, uptake of 25% in 2025-26 and 50% thereafter, and 60 people having tebentafusp each year from 2026-27, with pembrolizumab as the other treatment.
- The Scottish Medicines Consortium accepted tebentafusp for use within NHSScotland in the context of a Patient Access Scheme; the company's economic analysis used a partitioned survival model against pembrolizumab and nivolumab plus ipilimumab; the cost per year at list price is £525,928, and results in the pembrolizumab comparison showed a less favourable economic case.
- CADTH: at the sponsor-submitted price of $18,565 per vial, tebentafusp costs approximately $74,260 per 28-day cycle, and the ICER was $728,513 per QALY gained compared with investigator's choice of therapy; a price reduction of 91% would be required to reach $50,000 per QALY. In the CADTH base case, total costs and QALYs were $1,062,137 and 2.40 with tebentafusp and $147,736 and 1.14 with investigator's choice, and the ICER against nivolumab plus ipilimumab in previously untreated patients was $722,268 per QALY gained. Approximately 72% of OS and 92% of PFS with tebentafusp were accrued after the trial period by extrapolation. In the budget impact analysis from the perspective of a Canadian public health care payer, the 3-year budget impact for previously untreated patients was $32,731,194, and extending treatment duration by 1.9 months increased it to $77,670,205.
- In France, the Transparency Committee gave a favourable opinion for reimbursement and rated tebentafusp as providing a “moderate clinical added value (CAV III)”. In Germany, the G-BA found a “Hint for a considerable additional benefit” compared with dacarbazine, ipilimumab, and pembrolizumab, in approximately 100 to 130 eligible patients.
- A published analysis using a three-state partitioned survival model from the perspective of U.S. payers found an additional 0.47 QALYs (1.19 vs 0.72) and an incremental cost of $444,280 with tebentafusp, for an ICER of $953,230 per QALY against a willingness-to-pay threshold of $200,000 per QALY; tebentafusp became cost-effective at a unit price of $33.768 per µg.
- No assessment of uveal melanoma by the Institute for Clinical and Economic Review was found.

Source: [NICE technology appraisal guidance TA1027, recommendations (2025)](https://www.nice.org.uk/guidance/ta1027/chapter/1-Recommendations); [NICE technology appraisal guidance TA1027, information about tebentafusp (2025)](https://www.nice.org.uk/guidance/ta1027/chapter/2-Information-about-tebentafusp); [NICE technology appraisal guidance TA1027, committee discussion (2025)](https://www.nice.org.uk/guidance/TA1027/chapter/committee-discussion); [NICE resource impact summary report, tebentafusp (2025)](https://www.nice.org.uk/guidance/ta1027/resources/resource-impact-summary-report-13620251053/chapter/Resource-impact-summary-report); [Scottish Medicines Consortium advice SMC2910, tebentafusp (2026)](https://scottishmedicines.org.uk/media/10462/tebentafusp-kimmtrak-resubmission-final-june-2026-for-website.pdf); [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1); [CADTH pharmacoeconomic review, tebentafusp (2023)](https://www.ncbi.nlm.nih.gov/books/NBK596610/); [HAS Transparency Committee opinion, KIMMTRAK (2023)](https://www.has-sante.fr/jcms/p_3412130/en/kimmtrak-tebentafusp-uveal-melanoma); [G-BA resolution, tebentafusp reassessment D-995 (2024)](https://www.g-ba.de/downloads/91-1455-1022/2024-06-25_Current-Version_Tebentafusp_D-995_EN.pdf); [Luo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37650713/)

<a id="topic-4.1-4"></a>

### Summary: liver-directed therapy and revenue estimates

No cost-effectiveness study of radioembolization with yttrium-90 microspheres for uveal melanoma liver metastases was identified by a CADTH rapid response report, and none of chemosaturation by an NHS England evidence summary. Delcath estimates that 800 patients with uveal melanoma liver metastases in the United States and 1,200 in Europe may be eligible for HEPZATO or CHEMOSAT annually, an addressable market of approximately $600 million per year; the J-Code J9248 became effective on April 1, 2024, with transitional pass-through status under the Outpatient Prospective Payment System expiring on March 31, 2027. Truist analysts project around $800 million in peak revenue for darovasertib in first-line HLA-A2(-) metastatic uveal melanoma, and a second analyst estimate quoted by BioSpace is $415 million in peak revenues in the HLA-A∗02:01-negative population; Leerink notes that darovasertib could compete with KIMMTRAK in HLA-A∗02:01-positive uveal melanoma, an indication IDEAYA also intends to pursue.

Source: [CADTH rapid response report, radioembolization for uveal melanoma liver metastases (2018)](https://www.ncbi.nlm.nih.gov/books/NBK537723/); [NHS England evidence summary, chemosaturation for liver metastases from ocular melanoma (2015)](https://www.engage.england.nhs.uk/consultation/clinical-commissioning-wave6/user_uploads/a02-x05-chemosaturation-evidnc-rev.pdf); [Delcath Systems Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/872912/000162828026012019/dcth-20251231.htm); [BioSpace (2026)](https://www.biospace.com/drug-development/ideaya-and-serviers-eye-cancer-drug-heads-to-fda-after-delivering-best-in-class-efficacy)

<a id="topic-4.1-5"></a>

### Budget impact model or cost-effectiveness analysis of darovasertib plus crizotinib

No evidence found.

<a id="topic-4.1-6"></a>

### Darovasertib price

No evidence found.

<a id="topic-4.1-7"></a>

### Analyst estimates of peak revenue of darovasertib in first-line HLA-A∗02:01-negative metastatic disease

> “in first line HLA‑A2(-) metastatic uveal melanoma, Truist analysts wrote, projecting around $800 million peak revenue in this indication.”
> “Meanwhile, darovasertib could be competing with Immunocore’s Kimmtrak in HLA-A2*02:01 positive uveal melanoma, an indication that IDEAYA also intends to pursue, according to Leerink.”
> “it would be upside to our estimates of $415 million in peak revenues in the HLA-A*02:01-negative population,”

Source: [BioSpace (2026)](https://www.biospace.com/drug-development/ideaya-and-serviers-eye-cancer-drug-heads-to-fda-after-delivering-best-in-class-efficacy)

<a id="topic-4.1-8"></a>

### Company estimate of the annual incidence of primary and metastatic uveal melanoma and the HLA∗A2(-) share

> “We estimate the annual incidence of primary UM is >10,000 patients globally (including North America, Europe and Australia) and >3,000 patients in the United States.”
> “In metastatic UM, we estimate the annual incidence of newly diagnosed patients is between 4,000-5,000 globally and approximately 1,500 in the United States, which is based on data suggesting that approximately 50% of patients diagnosed in the primary setting ultimately progress to metastatic disease.”
> “Based on published data, we believe the majority of mUM patients are of the HLA*A2(-) serotype, representing between 60-65% of all mUM patients.”
> “In addition, several publications suggest there is clinical evidence of the loss of heterozygosity (LOH) of the HLA-alleles that could create discordance between a blood based versus tumor-based evaluation resulting in a potential over-reporting of HLA*A2(+) prevalence due to the loss of an allele with cancer progression.”
> “Currently, there are no FDA-approved systemic therapies for primary UM and no FDA-approved therapies for patients with HLA*A2(-) mUM.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-4.1-9"></a>

### Company statements on eligibility for the only approved systemic therapy and on other treatment options

> “< 50% patients eligible for the only approved systemic therapy”
> “Liver-directed therapy invasive and complex”
> “Off-label use of checkpoint inhibitors has limited efficacy”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-4.1-10"></a>

### Crizotinib wholesale acquisition cost, March 2026

| XALKORI package | Wholesale acquisition cost per package | Capsules per package |
| --- | --- | --- |
| 200 mg capsules | “$23,773.10” | “60” |
| 250 mg capsules | “$23,773.10” | “60” |

Source: [Pfizer XALKORI Connecticut price disclosure (2026)](https://cdn.pfizer.com/pfizercom/products/ctprescribers/XALKORICTPriceDisclosureShortForm03122026.pdf)

> “The prices listed are WAC prices, which represent Pfizer’s published list prices for the products sold to wholesalers, before any discount, rebate, or other price reduction.”
> “This information is being provided pursuant to CT House Bill 6669.  The information is accurate as of March 10, 2026.”

Source: [Pfizer XALKORI Connecticut price disclosure (2026)](https://cdn.pfizer.com/pfizercom/products/ctprescribers/XALKORICTPriceDisclosureShortForm03122026.pdf)

<a id="topic-4.1-11"></a>

### Tebentafusp wholesale acquisition cost, effective July 2026

> “Immunocore Commercial LLC announces the following price changes effective 1 July 2026.”

Source: [Immunocore KIMMTRAK price change notice (2026)](https://www.immunocore.com/download_file/force/321/0)

| Product | NDC | Updated wholesale acquisition cost, effective 1 July 2026 |
| --- | --- | --- |
| KIMMTRAK (tebentafusp-tebn) 100 mcg/0.5 mL vial | “80446-0401-01” | “$22,050.00” |

Source: [Immunocore KIMMTRAK price change notice (2026)](https://www.immunocore.com/download_file/force/321/0)

<a id="topic-4.1-12"></a>

### Tebentafusp net revenue and treatment of discarded drug under Medicare Part B

> “For the year ended December 31, 2025, we generated net revenue from sale of therapies of $400.0 million due to the sale of KIMMTRAK, of which $257.0 million was in the United States, $131.4 million in Europe, including the impact of a net decrease in estimated reserves related to prior periods of $6.0 million, and $11.6 million in International.”
> “However, in November 2023, CMS published the 2024 physician fee schedule that identified KIMMTRAK as a medicine that meets the criteria for unique circumstances under the 2021 Jobs Act, and was granted an increased applicable percentage of unused or discarded product volume subject to refund to CMS of 45%, as opposed to the 10% used for medicines without these unique circumstances.”
> “Therefore, we do not currently expect to be required to make refund payments under the CMS Rule.”

Source: [Immunocore Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/imcr-20251231.htm)

<a id="topic-4.1-13"></a>

### Pembrolizumab list price, September 2026

> “The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44.”
> “The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $25,034.88.”
> “The list price does not include other treatment-related costs. The list price is current as of September 2026.”

Source: [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/)

<a id="topic-4.1-14"></a>

### Manufacturer-published United States list prices of nivolumab, ipilimumab, dacarbazine, and the HEPZATO KIT

No evidence found.

<a id="topic-4.1-15"></a>

### Annual treatment costs of tebentafusp and comparator therapies in Germany

| Therapy | Annual treatment costs per patient, after statutory rebates |
| --- | --- |
| Tebentafusp | “€ 605,881.61 - € 619,990.00” |
| Dacarbazine | “€ 4,694.71 - € 12,497.72” |
| Ipilimumab | “€ 65,157.24” |
| Lomustine | “€ 1,291.70” |
| Nivolumab | “€ 75,915.32 - € 76,207.30” |
| Pembrolizumab | “€ 97, 656.46” |

Source: [G-BA resolution, tebentafusp reassessment D-995 (2024)](https://www.g-ba.de/downloads/91-1455-1022/2024-06-25_Current-Version_Tebentafusp_D-995_EN.pdf)

> “Costs after deduction of statutory rebates (LAUER-TAXE®) as last revised: 15 April 2024)”

Source: [G-BA resolution, tebentafusp reassessment D-995 (2024)](https://www.g-ba.de/downloads/91-1455-1022/2024-06-25_Current-Version_Tebentafusp_D-995_EN.pdf)

<a id="topic-4.1-16"></a>

### Added benefit and target population of tebentafusp in the German benefit assessment

| Item | Quoted record |
| --- | --- |
| Extent and probability of the additional benefit of tebentafusp compared to dacarbazine, ipilimumab and pembrolizumab | “Hint for a considerable additional benefit” |
| Number of HLA-A∗02:01-positive adult patients with unresectable or metastatic uveal melanoma eligible for treatment in Germany | “approx. 100 - 130 patients” |

Source: [G-BA resolution, tebentafusp reassessment D-995 (2024)](https://www.g-ba.de/downloads/91-1455-1022/2024-06-25_Current-Version_Tebentafusp_D-995_EN.pdf)

<a id="topic-4.1-17"></a>

### Tebentafusp list price and commercial arrangement in England

> “The list price for tebentafusp (200 micrograms per 1‑ml vial) is £10,114 (BNF online accessed September 2024).”
> “The company has a commercial arrangement. This makes tebentafusp available to the NHS with a discount. The size of the discount is commercial in confidence.”

Source: [NICE technology appraisal guidance TA1027, information about tebentafusp (2025)](https://www.nice.org.uk/guidance/ta1027/chapter/2-Information-about-tebentafusp)

<a id="topic-4.1-18"></a>

### NICE cost-effectiveness model structure, utilities, and testing costs for tebentafusp

> “The company presented a 3‑state partitioned survival model to estimate the cost effectiveness of tebentafusp compared with the usual treatments. The 3 health states were progression-free, progressed-disease and death. The starting age in the model was 62 years, in line with the mean age in the clinical trial (see section 3.5). A time horizon of 38 years, equating to a lifetime, was used.”
> “So, it used a time-to-death approach to calculate utility values in its model, which categorises utility based on the length of time before death.”
> “So, it used the utility values from NICE's technology appraisal guidance on pembrolizumab for advanced melanoma not previously treated with ipilimumab.”
> “It concluded that the time-to-death approach is not consistent with a model structure designed to reflect health-state utilities. But the choice of approach to estimate utility values was unlikely to be an important driver of the cost-effectiveness results.”
> “The company included the costs of HLA‑A*02:01 testing in its model. The committee agreed that it was appropriate to include the costs of testing in the model and that this would be simple to adopt in practice.”
> “The committee concluded that it was not appropriate to include a stopping rule in the model because the clinical rationale for it had not been adequately justified. After consultation, the company updated its base case to remove the 2‑year stopping rule.”

Source: [NICE technology appraisal guidance TA1027, committee discussion (2025)](https://www.nice.org.uk/guidance/TA1027/chapter/committee-discussion)

<a id="topic-4.1-19"></a>

### NICE end-of-life criteria, acceptable cost-effectiveness ratio, and decision for tebentafusp

> “The committee concluded that based on the clinical trial evidence tebentafusp meets the end-of-life criteria for treating advanced uveal melanoma.”
> “The committee concluded that if it were to accept the company's survival extrapolations, then the maximum acceptable ICER would be at the lower end of the range NICE considers a cost-effective use of NHS resources (£20,000 to £30,000 per QALY gained) to account for this uncertainty. When applying the end-of-life criteria an acceptable ICER would be around £39,000 per QALY gained.”
> “Tebentafusp has a patient access scheme. Because of confidential commercial arrangements for comparator treatments, the ICERs are confidential and cannot be reported here. Based on the committee's preferred assumptions, the ICER was within the range the committee had agreed would be a cost-effective use of NHS resources (see section 3.23).”

Source: [NICE technology appraisal guidance TA1027, committee discussion (2025)](https://www.nice.org.uk/guidance/TA1027/chapter/committee-discussion)

<a id="topic-4.1-20"></a>

### Population expected to be eligible for and to receive tebentafusp in England

| Measure | Current practice | 2025-26 | 2026-27 | 2027-28 | 2028-29 | 2029-30 |
| --- | --- | --- | --- | --- | --- | --- |
| People eligible for tebentafusp (rounded to nearest 5) | “120” | “120” | “120” | “120” | “125” | “125” |
| Uptake for tebentafusp (%) | “0” | “25” | “50” | “50” | “50” | “50” |
| People having tebentafusp each year (rounded to nearest 5) | “0” | “30” | “60” | “60” | “60” | “60” |

Source: [NICE resource impact summary report, tebentafusp (2025)](https://www.nice.org.uk/guidance/ta1027/resources/resource-impact-summary-report-13620251053/chapter/Resource-impact-summary-report)

> “The market share for tebentafusp is based on projections from the manufacturer and NHS England.”
> “The other treatment for the eligible population is pembrolizumab.”
> “Both tebentafusp and pembrolizumab are administered intravenously, but tebentafusp has more administrations. In addition, the first 3 administrations of tebentafusp require admission to hospital and 16 hours of monitoring.”

Source: [NICE resource impact summary report, tebentafusp (2025)](https://www.nice.org.uk/guidance/ta1027/resources/resource-impact-summary-report-13620251053/chapter/Resource-impact-summary-report)

<a id="topic-4.1-21"></a>

### Scottish Medicines Consortium advice, economic model, and annual list-price cost of tebentafusp

> “tebentafusp (Kimmtrak®) is accepted for use within NHSScotland.”
> “This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.”
> “The model was a partitioned survival model with states for pre-progression, progressed disease and death.”
> “Two comparators were included, pembrolizumab and nivolumab plus ipilimumab.”
> “Time to death utility values were used in the base case. The utility value for patients with 360 days or more before time to death was derived from the EQ-5D-5L data from IMCgp100-202.”
> “Medicines costs included drug acquisition costs, administration costs and subsequent treatment costs, health state costs, and the cost of adverse events.”
> “SMC considered results for decision-making that took into account all relevant PAS. SMC is unable to present these results due to competition law issues. Across the base case and scenario analyses, results in the pembrolizumab comparison showed a less favourable economic case.”
> “In addition, as tebentafusp is an orphan medicine, SMC can accept greater uncertainty in the economic case.”

Source: [Scottish Medicines Consortium advice SMC2910, tebentafusp (2026)](https://scottishmedicines.org.uk/media/10462/tebentafusp-kimmtrak-resubmission-final-june-2026-for-website.pdf)

| Medicine | Cost per year at list price, £ |
| --- | --- |
| Tebentafusp | “525,928” |

Source: [Scottish Medicines Consortium advice SMC2910, tebentafusp (2026)](https://scottishmedicines.org.uk/media/10462/tebentafusp-kimmtrak-resubmission-final-june-2026-for-website.pdf)

> “Costs calculated using the full cost of vials assuming wastage.”
> “Costs do not take any patient access schemes into consideration.”

Source: [Scottish Medicines Consortium advice SMC2910, tebentafusp (2026)](https://scottishmedicines.org.uk/media/10462/tebentafusp-kimmtrak-resubmission-final-june-2026-for-website.pdf)

<a id="topic-4.1-22"></a>

### CADTH cost-effectiveness estimate, required price reduction, and cost per cycle of tebentafusp

> “Treatment with Kimmtrak is expected to cost approximately $74,260 per 28-day cycle.”
> “Using the sponsor submitted price for tebentafusp and publicly listed prices for all other drug costs, the incremental cost-effectiveness ratio (ICER) for tebentafusp was $728,513 per quality-adjusted life-year (QALY) gained compared with investigator’s choice of therapy.”
> “A price reduction of 91% would be required for tebentafusp to achieve an ICER of $50,000 per QALY gained compared to investigator’s choice of therapy. Given the high degree of uncertainty in the long-term efficacy of tebentafusp, a higher price reduction may be warranted.”
> “Approximately 72% of OS and 92% of PFS associated with tebentafusp treatment were accrued after the trial period and based on extrapolation of the OS and PFS curves.”
> “The potential drug acquisition cost per patient is high. The health system resource use for tebentafusp is considerable relative to comparators.”
> “Drug wastage is quite significant as the standard dose is considerably less than the vial size (68 mcg vs 100 mcg) and single vial use is recommended.”

Source: [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1)

<a id="topic-4.1-23"></a>

### CADTH appraisal of the sponsor cost-utility model: comparator costs, structure, and health utilities

> “At the submitted price of $18,565 per vial, the cost of tebentafusp was $18,565 per week.”
> “In estimating the cost of IC of therapy, the sponsor weighted cost by the distribution of treatments used in the control arm of Study 202, which was 12.7% for ipilimumab, 81.7% for pembrolizumab, and 5.6% for chemotherapy with dacarbazine.”
> “This resulted in a per cycle cost of $10,375 for the first 4 doses and $6,876 for subsequent doses.”
> “The sponsor submitted a partitioned survival model that included 3 health states: preprogression, postprogression, and death (Appendix 3).”
> “Health utility declined by 0.084 after treatment discontinuation, reflecting patient preferences collected using the 5-Level EQ-5D instrument in Study 202. The sponsor could not identify any published literature on health utility data in patients with mUM or on modelled health utility for preprogression and postprogression states.”
> “In the CADTH base case, tebentafusp was associated with estimated total costs and QALYs of $1,062,137 and 2.40, compared with total costs and QALYs of $147,736 and 1.14 for patients receiving IC of therapy.”
> “CADTH conducted a scenario analysis in the previously untreated population and found that tebentafusp was associated with an ICER of $722,268 per QALY gained when compared with nivolumab plus ipilimumab combination therapy.”

Source: [CADTH pharmacoeconomic review, tebentafusp (2023)](https://www.ncbi.nlm.nih.gov/books/NBK596610/)

<a id="topic-4.1-24"></a>

### CADTH appraisal of the sponsor budget impact analysis: treatment duration, market share, and 3-year budget impact

> “The analysis was done from the perspective of a Canadian public health care payer over a 3-year time horizon (2023 to 2025).”
> “The sponsor estimated the population size using an epidemiology-based approach, with data obtained from published literature to estimate the number of patients eligible for treatment with tebentafusp.”
> “The sponsor estimated the duration of treatment with tebentafusp is twice as much as the comparators. The sponsor assumed no drug wastage in estimating treatment costs.”
> “In estimating the drug cost of tebentafusp, the sponsor adopted the median treatment duration of 8 cycles (24 doses) using data from IMCgp100-202 trial.”
> “In the IMCgp100-202 trial, treatment with tebentafusp was continued beyond initial progression for nearly half (43.3%) of the patients in the intervention arm. The median duration of treatment postdisease progression was 1.9 months for these patients.”
> “In CADTH reanalysis, the market share of tebentafusp was increased to 86% in year 1 and 2 in previously untreated patients.”
> “For previously untreated patients, the 3-year budget impact was estimated to be $32,731,194 (Year 1: $10,613,612; Year 2: $10,909,080; Year 3: $11,208,502).”
> “The results were sensitive to uncertainty in treatment duration of tebentafusp. Extending treatment duration of tebentafusp by 1.9 months increased the estimated 3-year total budget impact to $77,670,205.”

Source: [CADTH pharmacoeconomic review, tebentafusp (2023)](https://www.ncbi.nlm.nih.gov/books/NBK596610/)

<a id="topic-4.1-25"></a>

### French Transparency Committee assessment of tebentafusp

> “Favourable opinion for reimbursement as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.”
> “the Transparency Committee deems that KIMMTRAK 100 µg/0.5 mL (tebentafusp) concentrate for solution for infusion provides a moderate clinical added value (CAV III) as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.”

Source: [HAS Transparency Committee opinion, KIMMTRAK (2023)](https://www.has-sante.fr/jcms/p_3412130/en/kimmtrak-tebentafusp-uveal-melanoma)

<a id="topic-4.1-26"></a>

### Cost-effectiveness of tebentafusp from a United States payer perspective

> “A three-state partitioned survival model was developed to assess the costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) from the perspective of US payers.”
> “Compared with control group, tebentafusp therapy yielded an additional 0.47 QALYs (1.19 vs. 0.72 QALYs) and an incremental cost of $444 280 ($633 822 vs. $189 542).”
> “The resultant ICER of $953 230/QALY far outweighed the willingness-to-pay threshold of $200 000/QALY.”
> “Scenario analyses indicated that reducing the unit price of tebentafusp to $33.768/µg was associated with a favorable result of tebentafusp being cost-effective.”

Source: [Luo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37650713/)

<a id="topic-4.1-27"></a>

### Institute for Clinical and Economic Review assessment in uveal melanoma

No evidence found.

<a id="topic-4.1-28"></a>

### Cost-effectiveness of liver-directed therapy for uveal melanoma liver metastases

> “No relevant studies were identified or included regarding the cost-effectiveness of radioembolization with yittrium-90 microspheres versus other management options for the management of uveal melanoma liver metastases.”

Source: [CADTH rapid response report, radioembolization for uveal melanoma liver metastases (2018)](https://www.ncbi.nlm.nih.gov/books/NBK537723/)

> “No cost-effectiveness studies were identified to comment on the cost-effectiveness of this procedure.”

Source: [NHS England evidence summary, chemosaturation for liver metastases from ocular melanoma (2015)](https://www.engage.england.nhs.uk/consultation/clinical-commissioning-wave6/user_uploads/a02-x05-chemosaturation-evidnc-rev.pdf)

<a id="topic-4.1-29"></a>

### Company estimate of the population eligible for melphalan percutaneous hepatic perfusion and its reimbursement codes

> “Based on our research, an estimated 800 patients with uveal melanoma liver metastases in the United States, and 1,200 patients in Europe may be eligible for treatment with HEPZATO or CHEMOSAT annually.”
> “Eligible patients are those with limited extrahepatic disease that can be treated with resection or radiation, who are able to safely undergo general anesthesia, and who have metastases involving less than 50% of the liver parenchyma.”
> “Currently 55% of the patients are not eligible for KIMMTRAK, the only approved uveal melanoma systemic therapy, and most patients are treated with multiple lines of therapy.”
> “We estimate the annual addressable market for this indication in the United States and Europe is approximately $600 million per year.”
> “The J-Code (J9248) became effective on April 1, 2024. Delcath applied for and was granted transitional drug pass-through status for HEPZATO under the Outpatient Prospective Payment System for hospital outpatient services beginning on April 1, 2024 and expiring on March 31, 2027.”

Source: [Delcath Systems Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/872912/000162828026012019/dcth-20251231.htm)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
